Company Overview of YM BioSciences Inc.
YM BioSciences Inc., a drug development company, engages in developing hematology and cancer-related products. Its products include CYT387, a dual inhibitor of the JAK1 and JAK2 kinases, which has implicated in a family of hematological conditions known as myeloproliferative neoplasms, including myelofibrosis, as well in various other disorders comprising indications in hematology, oncology, and inflammatory diseases. The company is evaluating, CYT387, in a Phase I/II trial and a Phase II trial for the treatment of patients with myelofibrosis, a chronic debilitating disease in which a patient’s bone marrow is replaced by scar tissue. It is also developing nimotuzumab, a humanized monoclonal ...
5045 Orbitor Drive
Mississauga, ON L4W 4Y4
Founded in 1994
Key Executives for YM BioSciences Inc.
Vice President of Finance & Administration
President of Aerolef Division
Chief Medical Officer and Vice President of Regulatory Affairs
Head of Regulatory Affairs
Interim Head of Program Management
Compensation as of Fiscal Year 2014.
YM BioSciences Inc. Key Developments
YM BioSciences Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2012
Feb 7 13
YM BioSciences Inc. reported unaudited consolidated earnings results for the second quarter and six months ended December 31, 2012. For the quarter, the company reported revenue of CAD 3.9 million compared to CAD 0.4 million for the second quarter of fiscal 2012. Net loss was CAD 11.3 million or CAD 0.07 per basic and diluted share compared to CAD 6.6 million or CAD 0.06 per basic and diluted share for the same period last year. Loss before finance income and finance costs was CAD 5.48 million compared to CAD 8.03 million reported a year ago.
Revenue for the first six months of fiscal 2013 was CAD 4.2 million compared to CAD 0.6 million for the first six months of fiscal 2012. The increase was due to the sale of nimotuzumab licenses and subsequent recognition of all remaining deferred revenue relating to nimotuzumab licenses in December 2012. Net loss was CAD 20.0 million or CAD 0.13 per basic and diluted share compared to CAD 7.5 million or CAD 0.06 per basic and diluted share for the same period last year. Loss before finance income and finance costs was CAD 14.4 million compared to CAD 16.43 million reported a year ago. Net cash used in operating activities was CAD 12.97 million compared to CAD 13.74 million reported a year ago. Additions to property and equipment were CAD 18.54 million compared to CAD 10.22 million reported a year ago.
YM BioSciences Inc. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013
Feb 7 13
YM BioSciences Inc. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013 . Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.
YM BioSciences Inc., Special/Extraordinary Shareholders Meeting, Jan 31, 2013
Dec 21 12
YM BioSciences Inc., Special/Extraordinary Shareholders Meeting, Jan 31, 2013., at 10:00 US Eastern Standard Time. Location: Gowling Lafleur Henderson LLP. Agenda: To approve the plan of arrangement.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|